Two Kinds of Wanting: How Methamphetamine Craving Actually Works in the Brain

Here is something the treatment field tends to collapse into one word — “craving” — that turns out to be two genuinely distinct experiences with different neural signatures, different predictive values, and different implications for how treatment should work.

A study published in January 2026 in Frontiers in Public Health by Qiuping Huang, Zhenjiang Liao, Xuhao Wang, and colleagues at Hunan University of Chinese Medicine and Central South University set out to examine the relationship between craving and attentional bias in people with methamphetamine use disorder. What they found was a cleaner distinction than the field typically acknowledges.

Withdrawal craving is the persistent, background-state desire for the drug that people in early abstinence experience. It doesn’t require a trigger. It’s the thing that makes early recovery feel like being thirsty all the time. Huang and colleagues found that withdrawal craving was independently and significantly associated with attentional bias toward methamphetamine-related stimuli — when they showed participants images of meth-related objects alongside neutral objects, those with higher withdrawal craving were significantly slower to redirect attention away from the drug images (β = 8.135, p = 0.006). The correlation between attentional bias and withdrawal craving was r = 0.277 (p = 0.001).

Cue-induced craving is the acute, sharp desire triggered by an external stimulus — the smell of a certain environment, a friend who used, a specific song, a time of day. It’s impulsive and temporary. And in this study, cue-induced craving was not a significant independent predictor of attentional bias after researchers controlled for withdrawal craving.

That distinction matters clinically. Much of the existing psychological work on addiction craving — exposure therapy, cue reactivity training, the cognitive behavioral approaches that try to interrupt the cue-to-craving-to-use chain — is oriented primarily at cue-induced responses. If a person’s main problem is withdrawal craving, those approaches address the wrong mechanism. They’re good at helping someone manage the acute spike from a trigger; they’re not designed to reduce the low-grade, persistent state of wanting that characterizes early methamphetamine abstinence.

The Huang et al. study suggests that attentional bias training — exercises specifically designed to redirect attention away from drug-related stimuli — might be most useful for people in withdrawal distress, not people whose primary challenge is cue reactivity. Those are different populations at different stages of recovery, and they need different tools.

This is not a small distinction. Methamphetamine use disorder currently has no FDA-approved pharmacotherapy. The treatment options are mostly psychosocial: contingency management, CBT, motivational interviewing, residential programs. If the craving mechanism driving relapse in early abstinence is fundamentally different from the craving mechanism driving relapse after a cue encounter, then a blanket approach to “craving management” is going to be inadequate for a meaningful portion of people trying to stay off meth.

The question the study raises is the one the field needs to answer: are we matching treatment modalities to craving type — and if not, why not?

For more on stimulant use disorder and available treatments, visit /newsroom/substances/stimulants or start your search for care at /find-help.